HHS aims high in vax plan

The U.S. Department of Health and Human Services wants to surge manufacturing capacity for its vaccine programs. Pandemic influenza, emerging diseases and bioterrorism threats drive the need, according to the 2010 National Vaccine Plan.

The plan has two components: strategic objectives for the coming decade and an implementation plan. The objectives are supported by strategies.

Objective 1.2, for example, calls for research to develop and manufacture vaccines to prevent infectious diseases. It's supported by five strategies. One of them is development of "new approaches to vaccine manufacturing (e.g., rapid, flexible, and cost-effective)" that provide for expandable production during public health emergencies.

Another objective is the "timely integration" of manufacturing and regulatory advances that enhance product quality and patient safety. A related strategy involves developments to manufacturing sciences and quality systems, including "production technologies, in-process controls and testing, and identification of best practices in preventive quality systems and oversight."

- here's the plan

Suggested Articles

The FDA has lambasted the Torrent Pharmaceuticals in a warning letter for making OTC meds using water tainted with bacteria.

Eli Lilly is investing $400 million in its Indianapolis site to expand production of insulin and other diabetes meds, and add 100 jobs.

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.